<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860847</url>
  </required_header>
  <id_info>
    <org_study_id>Wakunaga of America Co., Ltd.</org_study_id>
    <nct_id>NCT00860847</nct_id>
  </id_info>
  <brief_title>Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)</brief_title>
  <official_title>Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Los Angeles Biomedical Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Los Angeles Biomedical Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Statement of Problem

           According to the National Fire Protection Association (NFPA), 43.7% of all firefighters
           that died on the job experienced sudden cardiac death. The job also affords an
           incredible amount of stress. Cholesterol therapy has been well demonstrated to reduce
           coronary plaque progression. However is certainly not the only factor in evaluating for
           progression of coronary artery disease (CAD), and other factors must play a role. Garlic
           therapy has been shown to retard atherosclerosis independently.

        2. Hypothesis and Specific Aims The hypothesis of this proposal is: In comparison to the
           placebo group, Aged Garlic Extract (AGE) therapy + Coenzyme Q10 (CoQ10) will be
           effective in slowing progression of coronary artery calcification (CAC) in firefighters
           with established atherosclerosis, independent of baseline blood pressure, statin use or
           other cardiovascular risk factors.

      Specific Aims:

        1. Compare the effects of cholesterol lowering effects in a firefighter population of
           patients under the influence of Aged Garlic Extract + CoQ10 or placebo.

        2. Compare whether degree of change in atherosclerotic coronary artery plaque burden will
           change at a different rate under the influence of Aged Garlic Extract + CoQ10 compared
           to placebo treatment.

        3. Compare whether Aged Garlic Extract + CoQ10 therapy induces changes in baseline values
           including biological and biochemical parameters, such as LDL cholesterol, homocysteine,
           C-reactive protein (CRP), and endothelial function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria

        -  Calcium scan with Agatston score &gt;20

        -  Age 35-84 years

        -  Subjects must provide written informed consent after the scope and nature of the
           investigation has been explained to them

        -  Subjects should be stable on their concomitant medications for at least 12 weeks prior
           to randomization

        -  Subjects who agree to refrain from supplemental garlic or significant dietary garlic

      Exclusion Criteria

        -  A contraindication to Aged Garlic Extract therapy including: known hypersensitivity to
           drug.

        -  Any unstable medical, psychiatric or substance abuse disorder that in the opinion of the
           investigator or principal investigator is likely to affect the subject's ability to
           complete the study or precludes the subject's participation in the study

        -  Weight in excess of 325 pounds

        -  Bleeding disorder

        -  History of myocardial infarction, stroke or life-threatening arrhythmia within the prior
           six months

        -  Resting hypotension (a resting systolic blood pressure of &lt;90 mm Hg) or hypertension (a
           resting blood pressure &gt; 170 mm Hg or a resting diastolic blood pressure of &gt;110 mm Hg)

        -  NYHA Class III or IV heart failure

        -  History of malignancy within the last 5 years (other than skin cancer) or evidence of
           active cancer which would require concomitant cancer chemotherapy

        -  Serum creatinine &gt; 1.4 mg/dl

        -  Triglycerides &gt; 400 at visit 1

        -  Diabetic subjects with HbA1c &gt; 12%

        -  Drug or alcohol abuse, or current intake of more than 14 standard drinks per week

        -  Concurrent enrollment in another placebo-controlled trial

        -  Presence of metal clips (i.e. bypass patients) or intracoronary stenting that preclude
           accurate measure of coronary calcification

        -  Partial ileal bypass or known gastrointestinal disease limiting drug absorption

        -  Current intake of garlic supplement or other prohibited drug (Appendix B)

        -  Current tobacco use

        -  Current use of anticoagulants (except for antiplatelet agents)

        -  Chronic renal failure

        -  Hematological or biochemical values at screening outside the reference ranges considered
           as clinically significant in the opinion of the investigator or PI

      Outcome Measures Primary - Rate of change in total coronary calcium scores by CT The Agatston
      score was calculated by multiplying the lesion area (mm^2) by a density factor. The density
      was measured in Hounsfield units, and score of 1 for 130-199 HU, 2 for 200-299 HU, 3 for
      300-399 HU, and 4 for 400 HU and greater.

      Secondary Change in blood values and endothelial function over 6 and 12 months:

        1. Plasma lipids: total plasma cholesterol and triglycerides, LDL-Cholesterol,
           HDL-Cholesterol, and VLDL-Cholesterol determined by the precipitation method;

        2. Endothelial markers and inflammation: C-reactive protein and Homocysteine, as well as
           GSH
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Change in Total Coronary Calcium Scores by Computed Tomography</measure>
    <time_frame>1 year</time_frame>
    <description>progression of coronary artery calcium deposits as determined by computed tomography as measured by the Agatston score: The Agatston score was calculated by multiplying the lesion area (mm^2) by a density factor. The density was measured in Hounsfield units, and score of 1 for 130-199 HU, 2 for 200-299 HU, 3 for 300-399 HU, and 4 for 400 HU and greater The endpoint is the mean change (end of study value - baseline value) in each group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1.Plasma Lipids: Total Plasma Cholesterol and Triglycerides, LDL-Cholesterol, HDL-Cholesterol, and VLDL-Cholesterol Determined by the Precipitation Method; 2. Endothelial Markers and Inflammation: C-reactive Protein and Homocysteine, as Well as GSH</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Coronary Atherosclerosis</condition>
  <condition>Coronary Artery Calcification</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>Aged Garlic Extract and Coenzyme Q10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AGE (1200 mg) and CoQ10 (120 mg)
This is a combination of aged garlic extract and co-enzyme Q10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>placebo pills will be given</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Aged garlic extract and Coenzyme Q10</intervention_name>
    <description>AGE (1200 mg) and CoQ10 (120 mg)</description>
    <arm_group_label>Aged Garlic Extract and Coenzyme Q10</arm_group_label>
    <other_name>Kyolic formula 110</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Calcium scan with Agatston score &gt;20

          -  Age 35-84 years

          -  Subjects must provide written informed consent after the scope and nature of the
             investigation has been explained to them

          -  Subjects should be stable on their concomitant medications for at least 12 weeks prior
             to randomization

          -  Subjects who agree to refrain from supplemental garlic or significant dietary garlic

        Exclusion Criteria:

          -  A contraindication to Aged Garlic Extract therapy including: known hypersensitivity to
             drug.

          -  Any unstable medical, psychiatric or substance abuse disorder that in the opinion of
             the investigator or principal investigator is likely to affect the subject's ability
             to complete the study or precludes the subject's participation in the study

          -  Weight in excess of 325 pounds

          -  Bleeding disorder

          -  History of myocardial infarction, stroke or life-threatening arrhythmia within the
             prior six months

          -  Resting hypotension (a resting systolic blood pressure of &lt;90 mm Hg) or hypertension
             (a resting blood pressure &gt; 170 mm Hg or a resting diastolic blood pressure of &gt;110 mm
             Hg)

          -  NYHA Class III or IV heart failure

          -  History of malignancy within the last 5 years (other than skin cancer) or evidence of
             active cancer which would require concomitant cancer chemotherapy

          -  Serum creatinine &gt; 1.4 mg/dl

          -  Triglycerides &gt; 400 at visit 1

          -  Diabetic subjects with HbA1c &gt; 12%

          -  Drug or alcohol abuse, or current intake of more than 14 standard drinks per week

          -  Concurrent enrollment in another placebo-controlled trial

          -  Presence of metal clips (i.e. bypass patients) or intracoronary stenting that preclude
             accurate measure of coronary calcification

          -  Partial ileal bypass or known gastrointestinal disease limiting drug absorption

          -  Current intake of garlic supplement or other prohibited drug (Appendix B)

          -  Current tobacco use

          -  Current use of anticoagulants (except for antiplatelet agents)

          -  Chronic renal failure

          -  Hematological or biochemical values at screening outside the reference ranges
             considered as clinically significant in the opinion of the investigator or PI
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew J Budoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://labiomed.org</url>
    <description>Contact Drs Budoff or Laidlaw for further information</description>
  </link>
  <reference>
    <citation>Libby P, Schoenbeck U, Mach F, Selwyn AP, Ganz P. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med. 1998 Feb 23;104(2A):14S-18S. Review.</citation>
    <PMID>9550502</PMID>
  </reference>
  <reference>
    <citation>Lau BH, Li L, Yoon P. Thymic peptide protects vascular endothelial cells from hydrogen peroxide-induced oxidant injury. Life Sci. 1993;52(22):1787-96.</citation>
    <PMID>8492641</PMID>
  </reference>
  <reference>
    <citation>Weissberg PL, Bennett MR. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jun 17;340(24):1928-9.</citation>
    <PMID>10375320</PMID>
  </reference>
  <reference>
    <citation>Raggi P, Callister TQ, Shaw LJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1272-7. Epub 2004 Apr 1.</citation>
    <PMID>15059806</PMID>
  </reference>
  <reference>
    <citation>Budoff MJ, Takasu J, Flores FR, Niihara Y, Lu B, Lau BH, Rosen RT, Amagase H. Inhibiting progression of coronary calcification using Aged Garlic Extract in patients receiving statin therapy: a preliminary study. Prev Med. 2004 Nov;39(5):985-91.</citation>
    <PMID>15475033</PMID>
  </reference>
  <reference>
    <citation>Steiner M, Lin RS. Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract. J Cardiovasc Pharmacol. 1998 Jun;31(6):904-8.</citation>
    <PMID>9641475</PMID>
  </reference>
  <reference>
    <citation>BEUTLER E, DURON O, KELLY BM. Improved method for the determination of blood glutathione. J Lab Clin Med. 1963 May;61:882-8.</citation>
    <PMID>13967893</PMID>
  </reference>
  <reference>
    <citation>Mao S, Bakhsheshi H, Lu B, Liu SC, Oudiz RJ, Budoff MJ. Effect of electrocardiogram triggering on reproducibility of coronary artery calcium scoring. Radiology. 2001 Sep;220(3):707-11.</citation>
    <PMID>11526270</PMID>
  </reference>
  <reference>
    <citation>Ahmadi N, Hajsadeghi F, Gul K, Vane J, Usman N, Flores F, Nasir K, Hecht H, Naghavi M, Budoff M. Relations between digital thermal monitoring of vascular function, the Framingham risk score, and coronary artery calcium score. J Cardiovasc Comput Tomogr. 2008 Nov;2(6):382-8. doi: 10.1016/j.jcct.2008.09.001. Epub 2008 Sep 26.</citation>
    <PMID>19083982</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <results_first_submitted>January 27, 2013</results_first_submitted>
  <results_first_submitted_qc>February 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2015</results_first_posted>
  <last_update_submitted>February 28, 2015</last_update_submitted>
  <last_update_submitted_qc>February 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Los Angeles Biomedical Research Institute</investigator_affiliation>
    <investigator_full_name>Matthew J. Budoff</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Progression of Atherosclerosis</keyword>
  <keyword>Aged garlic extract</keyword>
  <keyword>Biomarkers of inflammation</keyword>
  <keyword>Coronary Plaque Volume and coronary Stenosis</keyword>
  <keyword>Vascular function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>65 patients were recruited</recruitment_details>
      <pre_assignment_details>completed</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aged Garlic Extract and Coenzyme Q10</title>
          <description>Patients randomized to oral AGE (1200 mg) and CoQ10 (120 mg)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients randomized to placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aged Garlic Extract and Coenzyme Q10</title>
          <description>Patients randomized to oral AGE (1200 mg) and CoQ10 (120 mg)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients randomized to placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="6"/>
                    <measurement group_id="B2" value="55" spread="6"/>
                    <measurement group_id="B3" value="55" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Change in Total Coronary Calcium Scores by Computed Tomography</title>
        <description>progression of coronary artery calcium deposits as determined by computed tomography as measured by the Agatston score: The Agatston score was calculated by multiplying the lesion area (mm^2) by a density factor. The density was measured in Hounsfield units, and score of 1 for 130-199 HU, 2 for 200-299 HU, 3 for 300-399 HU, and 4 for 400 HU and greater The endpoint is the mean change (end of study value - baseline value) in each group.</description>
        <time_frame>1 year</time_frame>
        <population>all participants were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Aged Garlic Extract and Coenzyme Q10</title>
            <description>Patients randomized to oral AGE (1200 mg) and CoQ10 (120 mg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Change in Total Coronary Calcium Scores by Computed Tomography</title>
          <description>progression of coronary artery calcium deposits as determined by computed tomography as measured by the Agatston score: The Agatston score was calculated by multiplying the lesion area (mm^2) by a density factor. The density was measured in Hounsfield units, and score of 1 for 130-199 HU, 2 for 200-299 HU, 3 for 300-399 HU, and 4 for 400 HU and greater The endpoint is the mean change (end of study value - baseline value) in each group.</description>
          <population>all participants were analyzed</population>
          <units>Agatston score change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" spread="6"/>
                    <measurement group_id="O2" value="58" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1.Plasma Lipids: Total Plasma Cholesterol and Triglycerides, LDL-Cholesterol, HDL-Cholesterol, and VLDL-Cholesterol Determined by the Precipitation Method; 2. Endothelial Markers and Inflammation: C-reactive Protein and Homocysteine, as Well as GSH</title>
        <time_frame>1 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aged Garlic Extract and Coenzyme Q10</title>
          <description>Patients randomized to oral AGE (1200 mg) and CoQ10 (120 mg)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients randomized to placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Matthew Budoff</name_or_title>
      <organization>Los Angeles Biomedical Research Inst.</organization>
      <phone>310-222-4107</phone>
      <email>mbudoff@labiomed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

